ORGCAR-19.22

N/A

Report date: 2023/04/18 17:38:03

Base Information

Drug NameORGCAR-19.22

Drug Alias NameCD19.22 CAR-TCD19/CD22 CART cell therapy（Orgenesis）Anti-CD19/CD22 chimeric antigen receptor T cell therapy(Orgenesis)ORGCAR-19.22ORGCAR 19.22

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CD19Anti-CD22

TargetsB-lymphocyte antigen CD19CD22

Therapy Area/IndicationsLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesUnited Kingdom

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesKecellitics Biotech Company Ltd

China Registration ClassN/A

Develop Information

Active CompaniesOrgenesis Inc

Inactive CompaniesN/A

Active IndicationsLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A